Portal:Treatments/Selected article/3: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
m (format)
m (1 revision imported:Changed pages from staging wiki)
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
[[File:Ampligen.jpg|thumb|upright=0.5|center|Ampligen]]
[[File:Ampligen.jpg|thumb|center|Ampligen]]
'''Ampligen.jpg®︎''' (generic name '''rintatolimod''') is a drug with immunomodulatory and [[antiviral]] properties that is approved for [[Severe and very severe ME|severe ME/CFS]] in [[Argentina]]. Although Ampligen is not FDA-approved for ME/CFS it is available under early access or compassionate care programs in the [[United States]], EU countries, and Turkey.
'''Ampligen.jpg®︎''' (generic name '''rintatolimod''') is a drug with immunomodulatory and [[antiviral]] properties that is approved for [[Severe and very severe ME|severe ME/CFS]] in [[Argentina]]. Although Ampligen is not FDA-approved for ME/CFS it is available under early access or compassionate care programs in the [[United States]], EU countries, and Turkey.


Ampligen has been shown to raise the reduced [[natural killer cell]] (NK) function found in ME/CFS patients ('''[[Ampligen|more]]...''')
Ampligen has been shown to raise the reduced [[natural killer cell]] (NK) function found in ME/CFS patients ('''[[Ampligen|more]]...''')

Latest revision as of 21:52, November 4, 2023

Ampligen

Ampligen.jpg®︎ (generic name rintatolimod) is a drug with immunomodulatory and antiviral properties that is approved for severe ME/CFS in Argentina. Although Ampligen is not FDA-approved for ME/CFS it is available under early access or compassionate care programs in the United States, EU countries, and Turkey.

Ampligen has been shown to raise the reduced natural killer cell (NK) function found in ME/CFS patients (more...)